Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

The New England Journal of Medicine
Tait D ShanafeltMartin Tallman

Abstract

Data regarding the efficacy of treatment with ibrutinib-rituximab, as compared with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in patients with previously untreated chronic lymphocytic leukemia (CLL) have been limited. In a phase 3 trial, we randomly assigned (in a 2:1 ratio) patients 70 years of age or younger with previously untreated CLL to receive either ibrutinib and rituximab for six cycles (after a single cycle of ibrutinib alone), followed by ibrutinib until disease progression, or six cycles of chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab. The primary end point was progression-free survival, and overall survival was a secondary end point. We report the results of a planned interim analysis. A total of 529 patients underwent randomization (354 patients to the ibrutinib-rituximab group, and 175 to the chemoimmunotherapy group). At a median follow-up of 33.6 months, the results of the analysis of progression-free survival favored ibrutinib-rituximab over chemoimmunotherapy (89.4% vs. 72.9% at 3 years; hazard ratio for progression or death, 0.35; 95% confidence interval [CI], 0.22 to 0.56; P<0.001), and the results met the protocol-defined efficacy threshold for t...Continue Reading

References

Jul 11, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonThomas J Kipps
Jun 21, 2013·The New England Journal of Medicine·John C ByrdSusan O'Brien
Jan 10, 2014·The New England Journal of Medicine·Valentin GoedeMichael Hallek
Jun 3, 2014·The New England Journal of Medicine·John C ByrdUNKNOWN RESONATE Investigators
Jul 15, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas J SmithJames O Armitage
Dec 8, 2015·The New England Journal of Medicine·Jan A BurgerUNKNOWN RESONATE-2 Investigators
Jun 13, 2017·Journal of Oncology Practice·Jennifer Edelmann, John G Gribben
Aug 24, 2018·Molecular Medicine·Gerardo Ferrer, Emili Montserrat
Dec 7, 2018·The New England Journal of Medicine·Jennifer A WoyachJohn C Byrd

❮ Previous
Next ❯

Citations

Nov 26, 2019·The Cancer Journal·Nitin Jain, Susan OʼBrien
Nov 26, 2019·The Cancer Journal·Thomas J Kipps, Michael Y Choi
Nov 26, 2019·The Cancer Journal·Jan A Burger
Nov 26, 2019·The Cancer Journal·Christine E Ryan, Matthew S Davids
Nov 26, 2019·The Cancer Journal·Joanna M Rhodes, Stephen J Schuster
Nov 26, 2019·The Cancer Journal·Chaitra Ujjani, Bruce D Cheson
Oct 18, 2019·American Journal of Hematology·Michele Merli, Francesco Passamonti
Nov 27, 2019·Cancers·Bartosz PułaKrzysztof Jamroziak
Dec 24, 2019·Journal of Clinical and Experimental Hematopathology : JCEH·Hirohiko ShibayamaNozomi Yoshinari
Jan 29, 2020·JAAPA : Official Journal of the American Academy of Physician Assistants·Amber Koehler
Jan 31, 2020·Expert Opinion on Emerging Drugs·Stefano MolicaLuciano Levato
Feb 11, 2020·Expert Review of Hematology·Florian SimonPaul J Bröckelmann
Feb 18, 2020·British Journal of Haematology·Stephanie JordaensBarbara-Ann Guinn
Jan 21, 2020·European Journal of Haematology·Stefano MolicaEmili Montserrat
Feb 25, 2020·Expert Opinion on Biological Therapy·Iwona HusTadeusz Robak
Mar 13, 2020·Expert Opinion on Pharmacotherapy·Dirk L Kienle, Stephan Stilgenbauer
Apr 3, 2020·American Society of Clinical Oncology Educational Book·Farrukh T AwanJennifer A Woyach
Nov 17, 2019·Hematological Oncology·Stefano MolicaAaron Polliack
Apr 8, 2020·International Journal of Hematology·Junji Suzumiya, Jun Takizawa
Feb 23, 2020·Blood·William G Wierda, Francesco Paolo Tambaro
May 15, 2020·Journal of Clinical and Experimental Hematopathology : JCEH·Kensuke Kojima, Jan A Burger
Jul 17, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Deborah M Stephens, John C Byrd
Jul 22, 2020·JCO Global Oncology·Vishwanath SathyanarayananSwaminathan P Iyer
Jul 29, 2020·Blood Research·Jieun Uhm
Jul 30, 2020·The New England Journal of Medicine·Inhye E AhnAdrian Wiestner
Jul 30, 2020·The New England Journal of Medicine·Jan A Burger
Aug 14, 2020·Deutsche medizinische Wochenschrift·Paula CramerMichael Hallek
Sep 2, 2020·Expert Review of Hematology·Praveen Ramakrishnan Geethakumari, Farrukh Awan
Aug 2, 2020·British Journal of Pharmacology·Pedro F PinheiroM Matilde Marques
Sep 29, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Arnon P KaterJohn F Seymour
May 15, 2020·Expert Opinion on Investigational Drugs·Elżbieta Iskierka-Jażdżewska, Tadeusz Robak
Nov 30, 2019·Blood·Clemens-Martin Wendtner
Mar 14, 2020·Cancers·Riccardo MoiaGianluca Gaidano
Feb 29, 2020·Current Hematologic Malignancy Reports·Jason C Lee, Nicole Lamanna
Jul 24, 2020·Expert Review of Hematology·Candida Vitale, Alessandra Ferrajoli
Sep 19, 2020·Blood and Lymphatic Cancer : Targets and Therapy·Chaitra UjjaniMazyar Shadman

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Related Papers

The New England Journal of Medicine
Meletios A DimopoulosiNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia
Journal of Medicinal Chemistry
A H SolowayC H Cox
Annals of Thoracic and Cardiovascular Surgery : Official Journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
Yasunori Sohara
Pharmacological Research Communications
A Nicolin
© 2021 Meta ULC. All rights reserved